Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection
Primary Purpose
HCV Infection
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
GS-9256
GS-9190
Ribavirin
Peginterferon alfa-2a
Sponsored by
About this trial
This is an interventional treatment trial for HCV Infection focused on measuring Hepatitis C, HCV, GS-9256, GS-9190, Genotype 1
Eligibility Criteria
Inclusion Criteria:
- Adult subjects, ages 18-70
- Willing able to provide informed consent
- BMI between 18 and 36 kg/m2 (inclusive)
- Chronic HCV infection, genotype 1
- HCV RNA >/= 3 log, but < 7.2 log10 IU/ml at screen
- Liver biopsy, FibroTest, or FibroScan indicating absence of cirrhosis
- HCV treatment naïve with imminent plans to start treatment with PEG/RIBA
- QTcF </= 450 msec at screen
- ALT, AST, GGT < 5 X ULN at the screening visit
- Creatinine clearance >= 50 mL/min
- Absolute neutrophil count >= 1500/mm3
- Hemoglobin >/= 12 g/dL (female), >/= 13 g/dL (male)
- Males agree to use of effective contraception and refrain from sperm donation
- Able to comply with dosing instructions and study visits
- Of generally good health
Exclusion Criteria:
- Females of child-bearing potential or males with female partners who are pregnant or planning to become pregnant
- Infection with other HCV genotype or multiple HCV genotypes
- Poorly controlled diabetes
- Hemoglobinopathy or known retinal disease
- History of sarcoidosis or invasive malignancy
- Untreated or significant psychiatric illness
- Co-infection with hepatitis B virus or human immunodeficiency virus
- Chronic use of systemic immunosuppressive agents
- Autoimmune disorders
- Severe COPD
- History of significant cardiac disease
- Known cirrhosis
- Non-HCV chronic liver disease
- Transplantation
- Suspicion of hepatocellular carcinoma
- Bilirubin above the normal range or Gilbert's syndrome
- Decompensated liver disease
- Clinically significant illness
- GI disease that could interfere with absorption
- Acute porphyria
- Current excessive alcohol ingestion, averaging > 3 drinks/day for females and > 4 drinks/day for males or current binge drinking
- Positive urine drug screen
- History of difficult blood collection
- Significant recent blood loss
- Prohibited medications, including H2 antagonists, investigational agents
- Restricted fruits, fruit juices
- Hypersensitivity
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Arm 1
Arm 2
Arm 3
Arm Description
Outcomes
Primary Outcome Measures
Percentage of subjects achieving rapid virologic response (RVR)
AEs, physical examination and clinical laboratory test findings, vital signs, ECGs
Secondary Outcome Measures
Plasma pharmacokinetics
Viral resistance
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01072695
Brief Title
Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection
Official Title
A Phase 2, Randomized, Open-Label Trial of GS-9256 Plus GS-9190 Alone and in Combination With Ribavirin for 28 Days in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS-US-196-0112)
Study Type
Interventional
2. Study Status
Record Verification Date
May 2012
Overall Recruitment Status
Completed
Study Start Date
February 2010 (undefined)
Primary Completion Date
October 2010 (Actual)
Study Completion Date
January 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gilead Sciences
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This a phase 2, randomized, open-label trial of GS-9256 plus GS-9190, two oral anti HCV drugs, for 28 days with and without ribavirin (RIBA) and with pegylated interferon (PEG)/RIBA in adults with chronic Hepatitis C virus (HCV). In Part A, approximately thirty (30) subjects 18-70 years of age who meet study entry criteria will be randomized (in other words, selected at random, like flipping a coin) to one of the two treatment groups (GS-9256 plus GS-9190 or GS-9256 plus GS-9190 plus RIBA). In Part B, an additional fifteen (15) subjects will receive 75 mg GS-9256 BID plus 40 mg GS-9190 BID in combination with PEG/RIBA. After the 28-day treatment period, subjects will receive PEG/RIBA as standard of care (SOC).
Following randomization, subjects will return for a Baseline (Day 1) visit, at which time study medication will be dispensed and subjects will enter a 28 day treatment phase. During the treatment phase, subjects will receive oral study drugs twice daily for 28 days and PEG once weekly for Part B. Subjects then receive PEG/RIBA as local SOC starting on Day 28 (not provided as part of the study). Following completion of the 28-day treatment phase, subjects will be followed for approximately 72 weeks.
Detailed Description
GS-9256 (an HCV NS3 protease inhibitor) plus GS-9190 (non-nucleoside HCV NS5B inhibitor) will be administered for 28 days with and without RIBA (weight-based dosing) and with PEG/RIBA in treatment-naïve subjects with chronic genotype 1 HCV infection. In Part A, thirty (30) subjects with genotype 1 will be randomized to 75 mg GS-9256 BID plus 40 mg GS-9190 BID or 75 mg GS-9256 BID plus 40 mg GS-9190 BID plus RIBA 1000-1200 mg/day for 28 days. In Part B, an additional fifteen (15) subjects with genotype 1 will receive 75 mg GS-9256 BID plus 40 mg GS-9190 BID in combination with PEG/RIBA for 28 days. After the 28-day treatment period, subjects will receive PEG/RIBA as standard of care (SOC).
In Part A, for any subjects meeting pre-defined, individual, virologic criteria, PEG/RIBA standard of care will be started prior to Day 28.
Both PEG and RIBA will be administered at their currently approved dosages for treatment of HCV infection in accordance with appropriate labeling. Subjects will be monitored for safety (including ECG monitoring), antiviral activity, pharmacokinetics, and resistance 2-3 times weekly through Day 28.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HCV Infection
Keywords
Hepatitis C, HCV, GS-9256, GS-9190, Genotype 1
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
46 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Arm 1
Arm Type
Experimental
Arm Title
Arm 2
Arm Type
Experimental
Arm Title
Arm 3
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
GS-9256
Intervention Description
75 mg BID x 28 days
Intervention Type
Drug
Intervention Name(s)
GS-9190
Intervention Description
40 mg BID x 28 days
Intervention Type
Drug
Intervention Name(s)
Ribavirin
Other Intervention Name(s)
COPEGUS
Intervention Description
1000-1200 mg/day given BID
Intervention Type
Drug
Intervention Name(s)
Peginterferon alfa-2a
Other Intervention Name(s)
Pegasys
Intervention Description
180 ug q week
Primary Outcome Measure Information:
Title
Percentage of subjects achieving rapid virologic response (RVR)
Time Frame
Day 28
Title
AEs, physical examination and clinical laboratory test findings, vital signs, ECGs
Time Frame
Throughout first six weeks of study
Secondary Outcome Measure Information:
Title
Plasma pharmacokinetics
Time Frame
Throughout Day 28
Title
Viral resistance
Time Frame
Throughout study
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult subjects, ages 18-70
Willing able to provide informed consent
BMI between 18 and 36 kg/m2 (inclusive)
Chronic HCV infection, genotype 1
HCV RNA >/= 3 log, but < 7.2 log10 IU/ml at screen
Liver biopsy, FibroTest, or FibroScan indicating absence of cirrhosis
HCV treatment naïve with imminent plans to start treatment with PEG/RIBA
QTcF </= 450 msec at screen
ALT, AST, GGT < 5 X ULN at the screening visit
Creatinine clearance >= 50 mL/min
Absolute neutrophil count >= 1500/mm3
Hemoglobin >/= 12 g/dL (female), >/= 13 g/dL (male)
Males agree to use of effective contraception and refrain from sperm donation
Able to comply with dosing instructions and study visits
Of generally good health
Exclusion Criteria:
Females of child-bearing potential or males with female partners who are pregnant or planning to become pregnant
Infection with other HCV genotype or multiple HCV genotypes
Poorly controlled diabetes
Hemoglobinopathy or known retinal disease
History of sarcoidosis or invasive malignancy
Untreated or significant psychiatric illness
Co-infection with hepatitis B virus or human immunodeficiency virus
Chronic use of systemic immunosuppressive agents
Autoimmune disorders
Severe COPD
History of significant cardiac disease
Known cirrhosis
Non-HCV chronic liver disease
Transplantation
Suspicion of hepatocellular carcinoma
Bilirubin above the normal range or Gilbert's syndrome
Decompensated liver disease
Clinically significant illness
GI disease that could interfere with absorption
Acute porphyria
Current excessive alcohol ingestion, averaging > 3 drinks/day for females and > 4 drinks/day for males or current binge drinking
Positive urine drug screen
History of difficult blood collection
Significant recent blood loss
Prohibited medications, including H2 antagonists, investigational agents
Restricted fruits, fruit juices
Hypersensitivity
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Juan Betular
Organizational Affiliation
Gilead Sciences
Official's Role
Study Director
Facility Information:
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
City
Bruxelles
ZIP/Postal Code
1070
Country
Belgium
City
Clichy
ZIP/Postal Code
92110
Country
France
City
La Tronche
ZIP/Postal Code
38700
Country
France
City
Paris
ZIP/Postal Code
75475
Country
France
City
Duesseldorf
ZIP/Postal Code
40237
Country
Germany
City
Frankfurt
ZIP/Postal Code
60590
Country
Germany
City
Hamburg
ZIP/Postal Code
20099
Country
Germany
City
Hannover
ZIP/Postal Code
30625
Country
Germany
City
Wurzburg
ZIP/Postal Code
97080
Country
Germany
City
London
ZIP/Postal Code
E1 2AT
Country
United Kingdom
City
London
ZIP/Postal Code
SE5 9RS
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection
We'll reach out to this number within 24 hrs